ID: MRFR/HC/1074-CRR | April, 2018 | Region: Global | 108 pages | Cooked Research Reports
Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others) – Global Forecast Till 2023
Autism Spectrum Disorder (ASD) is a range of conditions caused by challenges with social skills, speech and nonverbal communication, repetitive behaviors, along with unique strengths and differences. This condition is caused by different combinations of genetic and environmental influences. Autism tends to show its most-obvious signs between two and three years of age. In various cases, it can be diagnosed within 18 months of the child’s birth.
The global autism disorder and treatment market has been identified as one of the rapidly growing industries, owing to rising prevalence of autism and Pervasive Developmental Disorder (PDD) and rising awareness about autism among the patient population. Autism disorder and treatment is observed as one of the significantly growing markets in the healthcare sector because of initiatives taken by the government of various nations and expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA).
With the upsurge in the market, there are some hindrances faced by the market such as a weak pipeline of drugs for autism disorder and unknown etiology and pathophysiology of ASD.
Global Autism Disorder & Treatment Market is expected to grow at a CAGR of 4.37% during the forecast period 2017–2023.
Source: Sources: World Health Organization (WHO), Centers for Disease Control's (CDC), Autism and Developmental Disabilities Monitoring (ADDM) society, U.S. Food and Drug Administration (FDA), Human Resources & Service Administration (HRSA), Autism Speaks, expert interview, market research future analysis, annual report, white paper, company presentation
The Global autism disorder & treatment market is segmented by type, treatment type, and drugs.
By type, it is segmented into Asperger Syndrome, Pervasive Developmental Disorder, and others.
By treatment type, it is segmented into ABA (applied behavioral analysis), hyperbaric oxygen therapy, chelation therapy, oxytocin therapy, and others.
By drug, it is segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. Anti-psychotics are further segmented into Abilify (aripiprazole) and Risperidone.
Figure: Global Autism Disorder & Treatment Market, by Treatment Type, 2016 (%)
Source Autism and Developmental Disabilities Monitoring (ADDM) society, U.S. Food and Drug Administration (FDA), Human Resources & Service Administration (HRSA), Autism Speaks, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
The global autism disorder & treatment market is segmented into four regions namely the Americas, Europe, Asia Pacific, and the Middle East & Africa, with Americas holding the largest market share followed by Europe. In Americas, North America accounted for the largest market owing to the increasing screening of autism cases in this region. Additionally, the approval and expected launch of the atypical anti-psychotic such as Latuda and Namenda is expected to generate increased sales in the U.S. post-approval. Asia Pacific is expected to be the fastest growing market while the Middle East & Africa exhibit steady and growth during the forecast period. As per the epidemiological studies conducted over the past 50 years have suggested that the prevalence of ASD is increasing globally. Some of the factors responsible for the increasing prevalence are improved awareness, expansion of diagnostic criteria, better diagnostic tools and improved reporting.
Some of the key players in this market are Pfizer Inc., Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Consern Pharma Private Limited, Novartis AG, Johnson & Johnson Services, Inc. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Coronis Partners Ltd., Curemark LLC, Heptares Therapeutics Limited, Intra-Cellular Therapies Inc., Saniona AB, and few others.